issued
on 08 Oct 2024
Last Applicant/ Owned by
4701 Sangamore Road, #100N
Bethesda
MD
20816
Serial Number
97916723 filed on 02th May 2023
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
scientific research and development; medical research; pharmaceutical research and development medical and healthcare information services pharmaceutical preparations for the treatment of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, Read More
medical and healthcare information services
N/A
N/A
scientific research and development; medical research; pharmaceutical research and development
N/A
N/A
pharmaceutical preparations for the treatment of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy side effects, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty
N/A
N/A
No 97916723
No Service Mark
No
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
08th Oct 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
13th Aug 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
13th Aug 2024 | PUBLISHED FOR OPPOSITION |
24th Jul 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
10th Jul 2024 | ASSIGNED TO LIE |
10th Jul 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
10th Jul 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
10th Jul 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
18th Jan 2024 | NOTICE OF REVIVAL - E-MAILED |
17th Jan 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |